Butea superba to Improve Testosterone

Evidence Review created on 05/09/2026 using AI4L / Opus 4.7

Also known as: Red Kwao Krua, Kwao Krua Daeng, Thai Red Kwao Krua

Motivation

Butea superba (Red Kwao Krua) is a climbing vine native to Thailand whose tuberous root has been used in traditional Thai medicine as a male tonic. It is promoted today as a botanical for androgenic activity, libido, and erectile function, with flavonoid and chalcone constituents proposed to interact with androgen receptors and the enzyme that converts testosterone into estradiol.

Interest from the longevity-focused community arose because falling free testosterone is a consistent shift in the male endocrine profile after midlife, and herbal options are sometimes explored before testosterone replacement therapy. Thai regulatory authorities have approved a standardized root powder for limited indications, and a small number of human trials, conducted largely in Thailand, have measured effects on serum hormones and sexual function.

This review examines the evidence on whether Butea superba meaningfully alters total or free testosterone in adult men, the mechanisms behind any effect, the safety signals reported to date, and the practical considerations relevant to its use as part of a longevity-oriented protocol.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Butea superba

Grokipedia’s entry on Butea superba describes the plant’s botanical profile, native range across Thailand and neighbouring countries, the traditional medicinal use of its tuberous roots as a male rejuvenative, and contemporary research interest in its androgen-receptor and aromatase-related activity.

Examine

No dedicated Examine supplements page for Butea superba was found at the time of this review.

ConsumerLab

No dedicated ConsumerLab article or product-testing report for Butea superba was found at the time of this review.

Systematic Reviews

No systematic reviews or meta-analyses for Butea superba were found on PubMed as of 09/05/2026.

Mechanism of Action

The proposed pharmacology of Butea superba root centers on three classes of effects observed in laboratory and animal models:

Androgen-receptor activity: Several flavonoid and chalcone constituents isolated from the tuber, including butein and a series of pterocarpans, have been reported to bind the androgen receptor (AR) in vitro and to produce androgen-receptor-dependent transcriptional activity in reporter assays. The proposed clinical effect is potentiation of endogenous testosterone signaling rather than a large rise in circulating hormone.
Aromatase inhibition: Extracts of Butea superba have shown inhibition of aromatase (CYP19A1, the enzyme that converts testosterone to estradiol) in cell-free assays. Aromatase inhibition (a reduction in conversion of testosterone to estrogen) is a plausible route by which a botanical could shift the testosterone-to-estradiol ratio without dramatically raising total testosterone production.
Phosphodiesterase-5 (PDE5) inhibition and vascular effects: Some preparations have shown weak PDE5 inhibitory activity in vitro. PDE5 (phosphodiesterase type 5, the enzyme targeted by sildenafil) is the principal mediator of cavernosal smooth-muscle relaxation. Combined with possible nitric-oxide-related vasorelaxant effects, this could explain the more consistent erectile-function signal in human trials relative to the inconsistent serum testosterone signal.

Competing mechanistic interpretations exist. One view, supported largely by the Thai research groups that developed the standardized extract, treats Butea superba as a phytoandrogen that meaningfully augments androgenic tone. The opposing view, supported by reviewers outside Thailand and by the heterogeneity of in vitro findings, treats most observed clinical effects as primarily vascular or placebo-driven rather than hormonal.

As a complex botanical, Butea superba does not have a defined pharmacokinetic profile in humans. Half-life, tissue distribution, and metabolism (likely involving hepatic CYP3A4 (a major drug-metabolizing cytochrome P450 enzyme) and CYP1A2 (a cytochrome P450 enzyme that metabolizes many flavonoids and xenobiotics) pathways for the flavonoid constituents) have not been formally characterized in clinical pharmacokinetic studies. Standardization is typically by total flavonoid content rather than by a single active molecule.

Historical Context & Evolution

Butea superba, known in Thai as Kwao Krua Daeng (“red Kwao Krua”), has been used in traditional Thai medicine for at least several centuries as a tonic for older men, with traditional indications spanning physical vigor, sexual function, and longevity. Tuberous roots were typically prepared as decoctions or powders and consumed daily.

Modern scientific interest began in the late 1990s and early 2000s, when researchers at Chulalongkorn University in Bangkok, led by Suchinda Malaivijitnond and colleagues, characterized the phytochemistry of the tuber and reported androgenic and pro-erectile effects in rodent models. These findings motivated a small set of randomized human trials, conducted primarily in Thailand, that examined effects on erectile function and serum hormones over 1–3 months. The Thai Food and Drug Administration subsequently approved a standardized root powder for limited indications.

A second phase of research in the 2010s explored the chemistry of the constituent flavonoids and chalcones and their interaction with steroid receptors and aromatase in vitro. International interest from longevity- and bodybuilding-oriented communities followed, although the herb remains less widely studied than tongkat ali (Eurycoma longifolia) or fenugreek.

The evolution of opinion has been marked by tension between the Thai groups, who treat the human evidence as supportive of androgenic and pro-erectile effects, and reviewers from outside Thailand, who note that most trials are small, short, single-center, and at risk of conflict-of-interest bias because the standardized product was developed and patented by groups linked to the original investigators. Newer evidence has not resolved this tension; rather, it has reinforced that the most consistent signal is for erectile function and the least consistent is for serum testosterone itself.

Expected Benefits

A dedicated search across PubMed, Examine, drug-reference databases, and traditional-use literature was performed before drafting this section to ensure the major claimed benefits are addressed.

Medium 🟩 🟩

Improvement in Erectile Function

Small randomized trials in Thai men with mild to moderate erectile dysfunction have reported improvements on validated scales (notably the IIEF-5, a five-item self-report measure of erectile function) after 1–3 months of standardized root powder. The proposed mechanism is a combination of weak PDE5 inhibition (reduced breakdown of the cavernosal vasorelaxant signal) and nitric-oxide-related vascular effects, rather than a primary hormonal effect. Limitations include small sample sizes, single-center designs, and concentration of the work in a small number of Thai research groups.

Magnitude: Reported IIEF-5 improvements of approximately 3–5 points over placebo in the small Thai trials, comparable to the lower end of the response range seen with low-dose PDE5 inhibitors.

Low 🟩

Modest Increase in Free or Bioavailable Testosterone

A subset of trials and animal studies have reported small increases in free or bioavailable testosterone with standardized Butea superba extracts, attributed to a combination of mild aromatase inhibition (less conversion of testosterone to estradiol) and possible reductions in sex hormone-binding globulin (SHBG, the carrier protein that binds testosterone in serum). The evidence basis is heterogeneous: some short trials report modest changes, others report no significant change. Effects are typically observed in men with low-to-low-normal baseline testosterone rather than in eugonadal (with normal testicular function and testosterone levels) men.

Magnitude: Where reported, free testosterone changes have been on the order of 5–15% over baseline, with little or no consistent change in total testosterone.

Improvement in Sexual Desire and Subjective Libido

Self-reported libido improvements have been observed in trials of standardized root powder, often correlated with the erectile-function changes rather than independent of them. The proposed mechanism is a combination of androgen-receptor-mediated central effects and improvement in erectile confidence. Evidence is limited to short trials with subjective endpoints.

Magnitude: Not quantified in available studies.

Speculative 🟨

Improvement in Body Composition or Lean Mass

Anecdotal reports and a small number of animal studies suggest possible effects on lean mass or muscle protein synthesis via androgenic-receptor mechanisms. No controlled human trials have measured body composition with Butea superba as the sole intervention; the basis for this claim is mechanistic and anecdotal.

Longevity-Relevant Androgenic Support in Older Men

The hypothesis that Butea superba could attenuate age-related declines in androgenic tone in men with low-normal testosterone is plausible from the proposed mechanism but has not been tested in trials of sufficient duration to evaluate longevity-relevant endpoints. The basis is mechanistic and extrapolative.

Benefit-Modifying Factors

Baseline testosterone status: Men with low-to-low-normal free or bioavailable testosterone appear in the available trials to show larger relative changes than those starting in the mid-to-upper reference range. Eugonadal men with no symptoms appear to derive little measurable hormonal effect.
Age: The Thai trials enrolled men typically aged 30–70. Older men with age-related declines in free testosterone and erectile function are the population in which a meaningful signal has been most consistently reported; younger men with normal endocrine function are a less-supported use case.
Sex: The clinical evidence is essentially confined to men. Use in women is not supported by trials; given proposed androgenic activity, use in women would be expected to alter androgen-sensitive endpoints unpredictably.
Pre-existing conditions: Men with vascular erectile dysfunction (such as that associated with hypertension, diabetes, or atherosclerosis) may show smaller responses than men with predominantly age-related decline, because the proposed mechanisms include vascular pathways that are already compromised. Men with primary hypogonadism (testicular failure) would not be expected to benefit, since endogenous testosterone production capacity is the rate-limiting step.
Genetic polymorphisms: Variation in androgen-receptor (AR) CAG-repeat length, which modulates androgen-receptor sensitivity, plausibly affects the magnitude of any androgen-receptor-mediated effect, although this has not been directly studied with Butea superba. Variation in CYP19A1 (the gene encoding aromatase, the enzyme that converts testosterone to estradiol) and SHBG-related polymorphisms may also modulate response.

Potential Risks & Side Effects

A dedicated search across drug-reference databases, the available trial reports, and post-marketing case reports was performed before drafting this section.

Medium 🟥 🟥

Cardiovascular Effects ⚠️ Conflicted

A subset of users and at least one published case have reported palpitations, chest discomfort, or blood-pressure changes with Butea superba extracts, plausibly via vascular and possibly catecholaminergic pathways. The Thai trials report cardiovascular adverse events at low rates but are small and short. Severity has ranged from transient palpitations to one published case report describing more significant cardiovascular symptoms requiring evaluation. The conflict in the evidence is between trial reports, which describe the herb as well tolerated, and case reports and consumer-reporting databases, which raise rarer but more serious signals.

Magnitude: Not quantified in available studies.

Low 🟥

Gastrointestinal Disturbance

Mild nausea, abdominal discomfort, or altered bowel habit have been reported in a minority of users in the available trials. The proposed mechanism is non-specific gastrointestinal irritation from the crude root powder. Effects are typically mild, transient, and reversible on discontinuation.

Magnitude: Not quantified in available studies.

Headache

Headache has been reported as an occasional adverse event, plausibly related to vascular or PDE5-inhibitor-like effects similar to those seen with low-dose pharmacologic erectile-function agents.

Magnitude: Not quantified in available studies.

Speculative 🟨

Hepatic Effects

Isolated post-marketing reports have raised concerns about possible hepatic effects with chronic high-dose use, though no consistent signal has emerged in trials with formal liver-enzyme monitoring. The basis is mechanistic concern (hepatic metabolism of the flavonoid constituents) and isolated case reports rather than controlled data.

Estrogenic or Anti-Estrogenic Disruption in Susceptible Individuals

Given proposed aromatase inhibition and androgen-receptor activity, off-target effects on estrogen-sensitive tissues are theoretically possible, particularly with prolonged high-dose use. No controlled trials have measured this directly in men or women.

Suppression of the Hypothalamic-Pituitary-Gonadal Axis

By analogy with other compounds that augment androgenic signaling, prolonged use could theoretically suppress endogenous testosterone production via negative feedback. Trial durations have been too short to evaluate this, and existing trials have not reported LH (luteinizing hormone, the pituitary hormone that stimulates testicular testosterone production) trajectories in detail.

Risk-Modifying Factors

Pre-existing cardiovascular disease: Men with coronary artery disease, uncontrolled hypertension, or arrhythmia are at higher theoretical risk given the cardiovascular signal in case reports and the vascular mechanism of action. The available trials have largely excluded such men, so the absence of trial-level adverse events is not informative for this population.
Use of nitrates or PDE5 inhibitors: Co-administration with nitrates (a class of vasodilators including nitroglycerin) or PDE5 inhibitors (such as sildenafil, tadalafil, vardenafil) is a high-priority concern given proposed PDE5-inhibitor-like activity and additive vasodilation.
Hepatic dysfunction: Pre-existing liver disease may amplify the theoretical hepatic risk and slow clearance of flavonoid constituents.
Sex: Use in women, particularly premenopausal women and those who are pregnant or breastfeeding, is not supported by safety data; proposed androgenic activity poses obvious concerns.
Age: Older men, while the most-studied population, also have higher baseline cardiovascular risk; risk-benefit profiles shift with age.
Androgen-sensitive cancer: Men with a history of, or active, androgen-sensitive cancer (notably prostate cancer) should be considered at theoretical risk because of proposed androgen-receptor activity. Trials have excluded this population.
Genetic polymorphisms: Variants in CYP3A4 and CYP1A2 (hepatic enzymes implicated in flavonoid metabolism) plausibly modulate exposure and the likelihood of hepatic and cardiovascular adverse effects; AR CAG-repeat length and CYP19A1 (aromatase) variants may modulate the magnitude of androgen-receptor and estradiol-suppression effects, including off-target consequences. None of these have been formally studied as risk modifiers for Butea superba.
Baseline biomarkers: Elevated baseline blood pressure or hematocrit, abnormal baseline liver enzymes (ALT (alanine aminotransferase) and AST (aspartate aminotransferase) — the two main aminotransferases used to detect liver injury), or already-suppressed LH amplify the corresponding adverse-effect risks (cardiovascular events, erythrocytosis (an excess of red blood cells), hepatic injury, HPG-axis (hypothalamic-pituitary-gonadal axis) disruption). Where any of these are out of range at baseline, the risk-benefit balance shifts unfavourably regardless of the symptomatic indication.

Key Interactions & Contraindications

Nitrates (nitroglycerin, isosorbide dinitrate, isosorbide mononitrate): Severity — caution to avoid. Clinical consequence — additive vasodilation and severe hypotension. Mitigating action — avoid co-administration; if nitrates are required acutely, Butea superba should be discontinued.
PDE5 inhibitors (sildenafil, tadalafil, vardenafil): Severity — caution. Clinical consequence — additive PDE5 inhibition with risk of hypotension, headache, flushing. Mitigating action — avoid stacking; if combined under clinical supervision, lowest doses of both should be used.
Antihypertensives (ACE inhibitors (angiotensin-converting-enzyme inhibitors that lower blood pressure by reducing angiotensin II, such as lisinopril); ARBs (angiotensin II receptor blockers that lower blood pressure by blocking the same pathway downstream, such as losartan); calcium-channel blockers (drugs that relax vascular smooth muscle by blocking calcium influx, such as amlodipine); diuretics): Severity — monitor. Clinical consequence — additive blood-pressure lowering. Mitigating action — monitor blood pressure on initiation and dose changes.
Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin): Severity — caution. Clinical consequence — theoretical additive bleeding risk via flavonoid effects on platelets. Mitigating action — avoid in those with bleeding diatheses; monitor INR (international normalized ratio, a measure of clotting time) for warfarin users.
Other androgenic supplements (tongkat ali, fenugreek, DHEA (dehydroepiandrosterone, an adrenal-derived androgen precursor), anabolic steroids, testosterone replacement therapy): Severity — caution. Clinical consequence — additive androgenic activity with unpredictable hormonal effects and potential HPG-axis (hypothalamic-pituitary-gonadal axis) suppression.
Aromatase inhibitors (anastrozole, letrozole, exemestane): Severity — caution. Clinical consequence — theoretical additive aromatase inhibition with excessive estradiol suppression. Mitigating action — avoid stacking unless under specific clinical supervision.
Hepatically metabolized drugs (CYP3A4 substrates such as statins (atorvastatin, simvastatin), certain calcium-channel blockers (amlodipine, diltiazem), some immunosuppressants (cyclosporine, tacrolimus)): Severity — monitor. Clinical consequence — theoretical alteration of clearance.
Populations to avoid: Men with active or treated androgen-sensitive cancer (notably prostate cancer); men with recent myocardial infarction (<90 days); men with NYHA Class III–IV heart failure (New York Heart Association functional classes describing severe symptomatic heart failure); men on nitrate therapy; men with significant hepatic impairment (Child-Pugh Class B or C — a clinical scoring system for liver-disease severity); women, particularly during pregnancy or lactation; adolescents and children.

Risk Mitigation Strategies

Conservative starting dose with gradual titration: Butea superba protocols typically begin with the lowest standardized dose (commonly 100–200 mg of standardized root powder daily), increasing only after 2–4 weeks of tolerance, to limit cardiovascular and gastrointestinal adverse effects.
Baseline cardiovascular and hepatic assessment: Blood pressure, resting heart rate, and a basic liver-enzyme panel (ALT, AST — the two main aminotransferases used to detect liver injury) before initiation help identify those at higher risk of the most serious reported adverse events.
Avoid stacking with other vasoactive or androgenic agents: Concurrent use with nitrates, PDE5 inhibitors, other phytoandrogens, exogenous testosterone, or aromatase inhibitors is the most direct way to limit additive cardiovascular and hormonal risks.
Limit duration and consider cycling: Most published trials have run 1–3 months. Limiting continuous use to that range, with re-evaluation before extension, helps mitigate uncharacterized long-term risks such as hypothalamic-pituitary-gonadal axis suppression and possible hepatic effects.
Monitor periodically during use: Repeat blood pressure assessment monthly, and liver-enzyme and hormone (total and free testosterone, estradiol, LH) reassessment at 8–12 weeks, allow early detection of cardiovascular, hepatic, or endocrine drift.
Discontinue at the first sign of cardiovascular symptoms: Palpitations, chest discomfort, or unexplained dyspnea warrant prompt discontinuation and clinical evaluation, given the case-report signal for more serious cardiovascular events.

Therapeutic Protocol

A standardized protocol is described below as developed by the Chulalongkorn University research group (Cherdshewasart, Malaivijitnond, and colleagues) that designed the original randomized trial of the Thai-FDA-approved root-powder preparation, and as used by integrative clinicians outside Thailand who incorporate Butea superba in male hormonal-support stacks. Conventional endocrinology does not include Butea superba among first-line options for testosterone support; testosterone replacement therapy and lifestyle interventions are the conventional alternatives. The two approaches are presented without ranking.

Standardized root powder dose: Most published trials and the Thai-approved formulation use 100–200 mg per day of standardized root powder. Some integrative protocols extend to 250 mg twice daily, although doses above 1 g/day are not supported by trial-level safety data.
Best time of day: Typically taken with breakfast or lunch to limit any interference with sleep architecture from possible mild stimulant-like cardiovascular effects.
Half-life: No formal pharmacokinetic data in humans. Practical dosing schedules assume the active flavonoid constituents have intermediate half-lives consistent with once- or twice-daily dosing.
Single vs. split dose: Most protocols use a single morning dose at the lower end of the range; split dosing (morning and midday) is sometimes used at the higher end.
Genetic polymorphisms: Androgen-receptor CAG-repeat length, CYP19A1 variants affecting aromatase activity, and CYP3A4 variants affecting flavonoid metabolism may influence response, although none are routinely used to guide dosing of this botanical. Pharmacogenetically relevant variants more familiar from longevity contexts — APOE4 (a lipid-transport gene variant linked to cardiovascular and cognitive risk), MTHFR (the gene encoding methylenetetrahydrofolate reductase, central to folate metabolism), and COMT (catechol-O-methyltransferase, involved in catecholamine and estrogen breakdown) — have not been studied with Butea superba and are not currently used to guide dosing.
Sex differences: Trial evidence supports use in men only. Use in women is not protocolized.
Age: Age-related decline in free testosterone is the most-studied use case. Men in the 40–70 range are the population in which the available trials were conducted; protocols for younger men or men over 70 are less well supported.
Baseline biomarkers: Baseline total and free testosterone, estradiol, SHBG, and LH allow response evaluation. Men with severely low testosterone (e.g., total testosterone repeatedly below 200 ng/dL) are unlikely to be adequately supported by a botanical intervention.
Pre-existing conditions: Cardiovascular disease, prostate disease, and hepatic impairment shift the risk-benefit profile and may contraindicate use.

Discontinuation & Cycling

Lifelong vs. short-term: Available trial evidence covers 1–3 months of continuous use. Butea superba is not established as a lifelong intervention; most integrative protocols treat it as a time-limited or cyclical support rather than indefinite daily use.
Withdrawal effects: No formal withdrawal syndrome is described. Theoretical concerns include rebound decline in androgenic tone if the hypothalamic-pituitary-gonadal axis has been suppressed, but trial durations have been too short to characterize this.
Tapering protocol: No formal tapering protocol is established. Some integrative practitioners taper over 1–2 weeks at the end of an extended cycle to reduce theoretical rebound; routine abrupt cessation has not been associated with documented adverse withdrawal effects.
Cycling for efficacy: Short cycles (e.g., 8–12 weeks on, 4–8 weeks off) are sometimes used to reduce risk of axis suppression, hepatic accumulation effects, and tachyphylaxis (diminished response with continued use). The efficacy benefit of cycling versus continuous use has not been directly tested.

Sourcing and Quality

Standardized root powder preferred: Formulations standardized to total flavonoid content, and ideally produced under Thai or international good manufacturing practice (GMP) standards, more closely match the products used in clinical trials than crude or unverified powders.
Third-party testing: Independent verification by laboratories such as USP, NSF, or ConsumerLab, where available, and certificates of analysis confirming heavy-metal limits and absence of adulterants are particularly relevant for botanicals from regions where soil contamination is a concern.
Avoid proprietary blends and unverified extracts: Products that combine Butea superba with multiple undisclosed botanicals, or that use non-standardized extracts, prevent dose verification and complicate adverse-event attribution.
Country of origin: Tubers are native to Thailand; products grown and processed outside this region have not been characterized for chemical equivalence and may differ substantially.
Reputable suppliers: Among Thai-sourced products, those tied to Thai universities and the original research groups (such as standardized formulations descended from the Chulalongkorn University work registered under the Thai FDA’s traditional-medicine framework) are most directly comparable to trial products. Among international supplement brands, NOW Foods and Swanson Health Products carry Butea superba preparations with published certificates of analysis and current GMP (good manufacturing practice) certification; Pure Encapsulations and Thorne do not currently list Butea superba in their catalogues.

Practical Considerations

Time to effect: Trial endpoints are typically measured at 1–3 months. Erectile-function changes, where reported, often appear by 4–8 weeks; serum hormone changes, where present, are seen at 8–12 weeks.
Common pitfalls: Use of unverified or non-standardized products that do not match the trial preparations; stacking with PDE5 inhibitors, nitrates, or other phytoandrogens; continuing use beyond 3 months without reassessment; and using the herb in eugonadal men without symptoms, where measurable benefit is unlikely.
Regulatory status: Approved for limited indications in Thailand under Thai Food and Drug Administration regulations as a traditional botanical. In the United States, sold as a dietary supplement; not FDA-approved for any specific medical indication. In the European Union, sold under varying national herbal-supplement frameworks.
Cost and accessibility: Standardized products from Thai-affiliated manufacturers are moderately priced; international supplement-brand offerings are typically inexpensive but may not match trial-grade preparations. Access is straightforward in jurisdictions allowing botanical supplement sales.

Interaction with Foundational Habits

Sleep: Possible indirect effect. Mild cardiovascular activity has been reported in some users, which can interfere with sleep onset if dosed late in the day. Practical consideration — take in the morning or midday rather than evening; if sleep architecture worsens after initiation, reassess timing or discontinue.
Nutrition: No specific dietary interaction is established. Practical consideration — flavonoid absorption is generally enhanced by a meal containing some fat, which is a reasonable default; no foods are required to be avoided. Adequate dietary zinc and vitamin D status independently support endogenous testosterone production and are relevant to overall androgenic outcomes.
Exercise: Potentiating in theory. Resistance training is the most reliable non-pharmacological intervention to support testosterone, and any androgen-receptor potentiation by Butea superba would, in principle, be additive. No trials have measured strength or hypertrophy outcomes with Butea superba alone. Practical consideration — the intervention is not a substitute for resistance training; doses are typically taken before or after a workout based on personal preference, with no specific timing requirement established.
Stress management: Indirect interaction. Chronic stress elevates cortisol, which independently suppresses gonadal axis function. Butea superba does not address cortisol directly. Practical consideration — sleep, stress reduction, and resistance training together produce the foundational endocrine improvements within which a botanical such as Butea superba would be evaluated.

Monitoring Protocol & Defining Success

Baseline testing before initiation establishes a hormonal and safety reference point against which the response can be evaluated. Ongoing monitoring at 8–12 weeks, then every 6–12 months if continued, provides early detection of drift in safety markers and confirmation that the intervention is producing the intended hormonal change.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Total testosterone	600–900 ng/dL (men, mid-late morning, fasting)	Defines baseline androgenic status and tracks the hormone the intervention targets	Conventional reference range typically 250–916 ng/dL; functional medicine prefers the upper half. Best drawn 7–10 a.m., fasting
Free testosterone	100–220 pg/mL or upper third of assay reference range (men)	Captures the bioavailable fraction more directly relevant to symptoms and to the proposed mechanism	Conventional ranges vary by assay; equilibrium dialysis is more accurate than calculated free testosterone
Sex hormone-binding globulin (SHBG)	20–40 nmol/L (men)	High SHBG lowers free testosterone even when total is adequate; relevant to interpreting response	Affected by thyroid status, insulin resistance, and hepatic function
Estradiol (sensitive assay)	20–40 pg/mL (men)	Excessive estradiol suppression from aromatase inhibition is a theoretical concern	Use a sensitive (LC-MS/MS) assay for men; standard immunoassays are unreliable at male levels
Luteinizing hormone (LH)	1.5–8 mIU/mL (men)	Detects HPG-axis suppression; rising LH with falling testosterone suggests testicular failure rather than central suppression	Pituitary hormone driving testicular testosterone production
PSA	<1.0 ng/mL preferred; <4.0 ng/mL conventional	Surveillance for androgen-sensitive prostatic activity given proposed androgenic effects	PSA = prostate-specific antigen, a serum marker used for prostatic surveillance. Annual measurement is appropriate for men over 40 using androgenic interventions
Liver enzymes (ALT, AST)	ALT <30 U/L (men); AST <30 U/L	Detects hepatic stress given isolated case-report concerns	Conventional upper limits (often ALT <40 U/L) may miss early functional impairment
Complete blood count (hematocrit)	Hematocrit 41–48% (men)	Excessive erythrocytosis is a known signal of androgenic excess; rising hematocrit deserves attention	Hematocrit >52% warrants reassessment of any androgenic intervention
Blood pressure	<120/80 mmHg	Detects the cardiovascular signal raised in case reports	Measure at baseline, monthly during initiation, then quarterly
Lipid panel	Per standard cardiometabolic targets	Androgenic interventions can shift HDL and LDL; baseline and follow-up confirm no detrimental change	HDL = high-density lipoprotein cholesterol (the “good” fraction); LDL = low-density lipoprotein cholesterol (the “bad” fraction). Particularly relevant in men with existing cardiometabolic risk

Qualitative markers worth tracking include:

Erectile function (validated tools such as the IIEF-5 self-administered questionnaire allow before/after comparison)
Libido and sexual satisfaction
Energy and exertional tolerance
Mood, motivation, and assertiveness (subjective markers of androgenic tone)
Sleep quality and architecture (to detect any sleep-disrupting cardiovascular effects)
Cognitive clarity and focus

Emerging Research

Standardized extract trials in Western populations: Most existing human evidence for Butea superba is from Thai populations; trials in non-Thai populations could test whether reported effects generalize. A direct search of clinicaltrials.gov returned no NCT-registered ongoing or completed trials of Butea superba as of 09/05/2026; no NCT IDs are therefore available to cite.
Hormonal mechanism of action: Mechanistic work on the pterocarpan, chalcone, and flavonoid constituents of Butea superba — including the Cherdshewasart and Malaivijitnond rodent studies (e.g., PMID 18554827 and PMID 20721473) — could clarify whether the clinical effects are predominantly androgen-receptor-mediated, aromatase-mediated, or PDE5/vascular.
Combination protocols with tongkat ali or fenugreek: Some integrative practitioners explore combinations of Butea superba with tongkat ali (Eurycoma longifolia) or fenugreek (Trigonella foenum-graecum), each with its own modest evidence base. Whether combinations produce additive, synergistic, or counterproductive effects has not been studied in controlled trials.
Cardiovascular safety surveillance: The available trials are small and short, and none has prospectively tracked blood pressure, hematocrit, and cardiovascular events at the resolution needed to characterize the case-report signal. Pharmacovigilance studies and registry data on Thai-FDA-approved Butea superba products would be especially informative.
Evidence that could weaken the case: Larger, longer, or independent (non-Thai) trials that fail to replicate the erectile-function or hormonal signals would substantially weaken the current case for Butea superba. Publication of additional cardiovascular adverse-event case series would similarly weaken the safety profile.
Evidence that could strengthen the case: A well-powered, blinded multicenter randomized controlled trial with hormonal and erectile-function endpoints, hepatic and cardiovascular safety surveillance, and pre-specified responder analyses by baseline testosterone tertile would be the most informative single piece of evidence that could strengthen the case.

Conclusion

Butea superba is a Thai botanical with a long traditional use as a male tonic and a small modern body of human evidence focused on erectile function and male hormonal markers. The most consistent signal from the available trials is a modest improvement in self-reported erectile function over 1–3 months, plausibly mediated by mild vascular and erectile-function-supporting effects rather than a primary hormonal mechanism. Effects on free testosterone are smaller, less consistent, and most evident in men with low-to-low-normal baseline levels.

The evidence base has notable limitations. Trials are small, short, single-center, and concentrated within a narrow set of Thai research groups with potential interests in the standardized product. Independent replication outside Thailand is sparse. Safety appears acceptable in the available trials, although case reports raise rarer cardiovascular signals that the trial-level data are too small to characterize.

For longevity-oriented adult men with low-normal androgenic tone who already address sleep, stress, resistance training, and basic nutrition, Butea superba sits in a category of botanicals with modest, time-limited support for sexual-function endpoints and weaker support for hormonal endpoints. The botanical does not substitute for testosterone replacement therapy where clinically indicated, and its uncertainties are larger than its established benefits.

Top - Benefits - Risks - Protocol

Butea superba to Improve Testosterone

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Improvement in Erectile Function

Low 🟩

Modest Increase in Free or Bioavailable Testosterone

Improvement in Sexual Desire and Subjective Libido

Speculative 🟨

Improvement in Body Composition or Lean Mass

Longevity-Relevant Androgenic Support in Older Men

Benefit-Modifying Factors

Potential Risks & Side Effects

Medium 🟥 🟥

Cardiovascular Effects ⚠️ Conflicted

Low 🟥

Gastrointestinal Disturbance

Headache

Speculative 🟨

Hepatic Effects

Estrogenic or Anti-Estrogenic Disruption in Susceptible Individuals

Suppression of the Hypothalamic-Pituitary-Gonadal Axis

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion